title: Rationale for iloperidone in the treatment of posttraumatic stress disorder.
abstract: Multiple controlled efficacy studies are available to support the use of psychotropic medications in the treatment of posttraumatic stress disorder symptoms. Iloperidone, a recently approved atypical antipsychotic, has yet to be evaluated in such a manner. This unique agent has the highest affinity of all antipsychotics toward alpha-1 receptors. Antagonism of central nervous system alpha-1 receptors has been implicated in certain aspects of posttraumatic stress disorder, as evidenced by the beneficial role of prazosin in treating nightmares. Additional reduction in hypervigilance may occur through blockade of dopamine receptor D2 and serotonin receptors in the 5-HT2 family. Further investigation of iloperidone is warranted in the treatment of patients with posttraumatic stress disorder due to its unique receptor binding profile.
authors.affiliation: Dr. Shuman is Assistant Professor, Pharmacy Practice, Rosalind Franklin University of Medicine and Science College of Pharmacy, North Chicago, Illinois, and Pharmacy Specialist, Mental Health, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois; Dr. McGrane is a Clinical Pharmacist, St. Joseph Medical Center, Polson, Montana.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Shuman
authors.affiliation: Dr. Shuman is Assistant Professor, Pharmacy Practice, Rosalind Franklin University of Medicine and Science College of Pharmacy, North Chicago, Illinois, and Pharmacy Specialist, Mental Health, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois; Dr. McGrane is a Clinical Pharmacist, St. Joseph Medical Center, Polson, Montana.
authors.forename: Ian R
authors.initials: IR
authors.lastname: Mcgrane
keywords: Antidepressants; Antipsychotic; iloperidone; posttraumatic stress disorder; pre-pulse inhibition